Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Surg Neurol Int ; 11: 294, 2020.
Article in English | MEDLINE | ID: mdl-33093971

ABSTRACT

BACKGROUND: Cavernous malformations prevalence ranges from 0.4 to 0.6% and accounts for 5-15% of all central nervous system vascular malformations. Pineal cavernomas constitute <1% of all locations published in the literature, with a total of 26 cases reported, only 5 regarding the pediatric population until 2020. Overall annual hemorrhage rate is 2.4%. Symptoms are often due to hydrocephalus and intracranial hypertension. CASE DESCRIPTION: We report a case of a 5-year-old child with visual disturbances, headache, and progressive neurologic deterioration. MR showed a lesion in the pineal region and triventricular hydrocephalus. She was submitted to endoscopic third ventriculostomy and total excision of the lesion by the infratentorial supracerebellar approach a few days later. Histopathological examination confirmed a pineal cavernous malformation. The patient returned to her normal life without any neurologic deficit and a normal development. CONCLUSION: The ideal treatment is primary lesion removal; however, due to the infrequency and because it is a curable lesion, studies seeking to deepen the knowledge of this disease are considered relevant.

2.
BMC Cancer ; 18(1): 1259, 2018 Dec 17.
Article in English | MEDLINE | ID: mdl-30558563

ABSTRACT

BACKGROUND: Genetic alterations in pediatric primary brain tumors can be used as diagnostic and prognostic markers and are the basis for the development of new target therapies that, ideally, would be associated with lower mortality and morbidity. This study evaluates the incidence and interplay of the presence of BRAF V600E mutation and chromosomal 9p21 deletions in a series of 100 pediatric gliomas, aiming to determine the role of these alterations in recurrence and malignant transformation, and to verify if they could be used in the clinical set for stratifying patients for tailored therapies and surveillance. METHODS: Sanger sequencing was used for the assessment of BRAF mutations at exon 15 and Fluorescent In Situ Hybridization (FISH) with BAC: RP11-14192 for the detection of 9p21 alterations. Expression levels of the CDKN2A and MTAP by real-time PCR were evaluated in cases with 9p21 deletions. Statistical analysis of genetic and clinical data was performed using Graph Pad Prism 5 and SPSS Statistics 24 software. RESULTS: In our cohort it was observed that 7 /78 (8,9%) of the low-grade tumors recurred and 2 (2,6%) showed malignant transformation. BRAF V600E mutations were detected in 15 cases. No statistically significant correlations were found between the presence of BRAF V600E mutation and patient's morphologic or clinical features. Deletions at 9p21 abrogating the CDKN2A/B and MTAP loci were rare in grade I gliomas (12.2%, p = 0.0178) but frequent in grade IV gliomas (62.5%, p = 0.0087). Moreover it was found that deletions at these loci were correlated with a shorter overall survival (p = 0.011) and a shorter progression-free survival (p = 0.016). CONCLUSIONS: It was demonstrated that in these tumors BRAF V600E mutated and that CDKN2A/B MTAP co-deletions may be used for stratifying patients for a stricter surveillance. The Investigating and defining if glial tumors with CDKN2A/B and MTAP homozygous loss may be vulnerable to new forms of therapy, namely those affecting the methionine salvage pathway, was proven to be of importance.


Subject(s)
Brain Neoplasms/genetics , Chromosomes, Human, Pair 9/genetics , Glioma/genetics , Mutation , Proto-Oncogene Proteins B-raf/genetics , Adolescent , Child , Child, Preschool , Cohort Studies , Cyclin-Dependent Kinase Inhibitor p15/genetics , Cyclin-Dependent Kinase Inhibitor p16/genetics , Female , Gene Deletion , Humans , In Situ Hybridization, Fluorescence , Infant , Male , Phosphorylases/genetics , Sequence Analysis, DNA
3.
Mol Genet Genomic Med ; 4(3): 303-11, 2016 May.
Article in English | MEDLINE | ID: mdl-27247958

ABSTRACT

BACKGROUND: Autosomal recessive distal renal tubular acidosis (dRTA) is a rare disease characterized by a hyperchloremic metabolic acidosis with normal anion gap, hypokalemia, hypercalciuria, hypocitraturia, nephrocalcinosis, and conserved glomerular filtration rate. In some cases, neurosensorial deafness is associated. dRTA is developed during the first months of life and the main manifestations are failure to thrive, vomiting, dehydration, and anorexia. METHODS: Nine unrelated families were studied: seven children, a teenager, and an adult with dRTA. Hearing was preserved in four children. Coding regions of the genes responsible for recessive dRTA were analysed by Sanger sequencing. RESULTS: Molecular defects were found in the genes ATP6V1B1 and ATP6V0A4. We identified three homozygous variants in ATP6V1B: a frameshift mutation (p.Ile386Hisfs*56), a nucleotide substitution in exon 10 (p.Pro346Arg), and a new splicing mutation in intron 5. Three patients were homozygous for one novel (p.Arg743Trp) and one known (p.Asp411Tyr) missense mutations in the ATP6V0A4 gene. Three patients were compound heterozygous: one proband displayed two novel mutations, the frameshift mutation p.Val52Metfs*25, and a large deletion of exons 18-21; two probands showed the missense mutation p.Asp411Tyr and as a second mutation, p.Arg194Ter and c.1691+2dup, respectively. CONCLUSION: ATP6V0A4 and ATP6V1B1 genes were involved in recessive dRTA of Mexican families. All ATP6V1B1 mutations detected were homozygous and all patients developed sensorineural hearing loss (SNHL) early in infancy. ATP6V0A4 mutations were found in one infant and three children without SNHL, and in one teenager and one adult with SNHL confirming the phenotypic variability in this trait. The mutation p.Asp411Tyr detected in four Mexican families was due to a founder effect. Screening of these mutations could provide a rapid and valuable tool for diagnosis of dRTA in this population.

5.
Eng. sanit. ambient ; 14(4): 449-454, out.-dez. 2009. ilus, tab
Article in Portuguese | LILACS | ID: lil-537651

ABSTRACT

A coagulação é uma etapa de tratamento da água, e para tal são realizados ensaios de teste de jarro que permitem determinar a dose necessária dos agentes coagulante e químico de ajuste de pH no processo de coagulação. Contudo, esses ensaios demoram a ser executados, não respondendo em tempo real às mudanças da qualidade da água bruta. Para superar tal limitação, redes neurais artificiais multicamadas foram construídas (e seus pesos sinápticos ajustados), validadas e testadas para predizer a dosagem do hidróxido de sódio e do sulfato de alumínio - utilizados como agentes químico de ajuste de pH e coagulante, respectivamente. Os resultados dos modelos obtidos são compatíveis com os dados experimentais tendo em vista que as incertezas das estimativas estão na mesma ordem de grandeza das faixas indicadas pelos ensaios realizados de testes de jarro ao longo de quase seis anos.


Coagulation is a stage in water treatment and, for this, jar tests are performed, which allows determining the optimal coagulant and alkalizer doses in coagulation process. However, these tests are time-consuming and do not enable real-time responses to changes in raw water quality. To overcome these limitations, artificial multilayer perceptron neural networks were built, trained, validated and tested to predict the aluminum and sodium hydroxide doses - used as coagulant and alkalizer, respectively. The results of these models are encouraging to consider that the estimated uncertainties have the same order of the variation limits magnitude indicated by the jar tests for almost a six-year period.

6.
Perit Dial Int ; 26(1): 78-84, 2006.
Article in English | MEDLINE | ID: mdl-16538879

ABSTRACT

BACKGROUND: The frequency of low-turnover bone disease (LTBD) in patients with chronic kidney disease (CKD) has increased in past years. This change is important because LTBD is associated with bone pain, growth delay, and higher risk for bone fractures and extraosseous calcifications. LTBD is a histological diagnosis. However, serum markers such as parathyroid hormone (PTH) and calcium levels offer a noninvasive alternative for diagnosing these patients. OBJECTIVE: To describe the prevalence of LTBD in pediatric patients with renal failure undergoing some form of renal replacement therapy, using serum calcium and intact PTH levels as serum markers. METHODS: In this cross-sectional study, 41 children with CKD undergoing dialysis treatment (31 on continuous ambulatory peritoneal dialysis and 10 on hemodialysis) were included. There were no inclusion restrictions with respect to gender, cause of CKD, or dialysis modality. The children were studied as outpatients. The demographic data, CKD course, time on dialysis, phosphate-binding agents, and calcitriol prescription were registered, as well as weight, height, Z-score for height, linear growth rate, and Z-score for body mass index. Serum calcium, phosphorus, aluminum, PTH, alkaline phosphatase, osteocalcin, glucose, creatinine, urea, cholesterol, and triglycerides were measured. RESULTS: There were 20 (48.8%) children with both PTH < 150 pg/mL and corrected total calcium >10 mg/dL who were classified as having LTBD[(+)]; the remaining 21 (51.2%) children were classified as having no LTBD[(-)]. The LTBD(+) patients were younger (11.2 +/- 2.7 vs 13.2 +/- 2.4 years, p < 0.01) but they had no differences regarding Z-scores for height. Linear growth in 6 months was less than expected in both groups (-0.15 +/- 0.23 cm/month), but the difference between expected and observed growth was higher in the LTBD(+) group (-0.24 +/- 0.14 vs -0.07 +/- 0.28 cm/mo, p < 0.03). LTBD(+) patients also had lower serum creatinine (8.69 +/- 2.75 vs 11.19 +/- 3.17 mg/dL, p < 0.01), higher serum aluminum levels [median (range) 38.4 (9 - 106) vs 28.1 (9 - 62) microLg/L, p < 0.05], and lower systolic blood pressure (112.0 +/- 10.3 vs 125.0 +/-1 2.9 mmHg, p < 0.015) and diastolic blood pressure (76.0 +/- 9.7 vs 84.5 +/- 8.2 mmHg, p < 0.017). A significant correlation was found between PTH and alkaline phosphatase (r = 0.68, p < 0.001), but not between PTH and aluminum. CONCLUSION: The LTBD(+) biochemical profile was found in 48.8% of the children and was associated with impaired linear growth. Aluminum contamination, evidenced by higher serum aluminum levels, may have had a pathogenic role in these disorders. Higher systolic and diastolic blood pressure levels may be related to higher serum PTH levels.


Subject(s)
Calcium/blood , Chronic Kidney Disease-Mineral and Bone Disorder/blood , Kidney Failure, Chronic/therapy , Parathyroid Hormone/blood , Renal Dialysis , Adolescent , Biomarkers/blood , Child , Child, Preschool , Chronic Kidney Disease-Mineral and Bone Disorder/epidemiology , Chronic Kidney Disease-Mineral and Bone Disorder/etiology , Cross-Sectional Studies , Disease Progression , Female , Follow-Up Studies , Humans , Incidence , Kidney Failure, Chronic/complications , Male , Mexico/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL